A More Grounded Gathering
Psychedelic Science 2025 was held in Denver, Colorado from June 16 to 20, bringing together thousands of researchers, therapists, advocates, and policymakers to assess the future of psychedelic-assisted therapy. Although smaller than its 2023 debut—with around 8,000 attendees instead of 12,000—the event was no less impactful. Organized by the Multidisciplinary Association for Psychedelic Studies (MAPS), the conference reflected a maturing movement facing real-world obstacles.
This year’s theme, “The Integration,” spoke volumes. It emphasized the need to merge scientific evidence, legal reform, clinical practice, and cultural change to ensure a sustainable future for psychedelic therapies.
Setbacks in the Psychedelic Movement
While enthusiasm for psychedelics remains high, the field has encountered major roadblocks. MAPS founder Rick Doblin opened the conference by acknowledging that the psychedelic movement has taken some hits. Most notably, the FDA rejected MAPS’ application to approve MDMA-assisted psychotherapy for PTSD—despite the treatment being granted “breakthrough therapy” status in 2017.
In addition, Massachusetts voters turned down a ballot initiative to legalize natural psychedelics, and several psychedelic startups have faced financial instability. These challenges have led to deeper reflection within the field about its next steps.
Psychedelic Therapy Without Psychotherapy?
One of the more contentious topics at Psychedelic Science 2025 was how psychedelic treatments should be delivered. While MAPS promotes combining psychedelics with guided psychotherapy, some pharmaceutical companies are pushing for approval of synthetic psychedelic drugs without the therapeutic support component.
This divide may influence how the FDA and the public perceive future treatments. Rick Doblin warned that separating the medicine from the therapy could reduce the effectiveness and safety of psychedelic healing.
The Role of Therapy in Psychedelic Science 2025
Many booths at the conference showcased therapeutic services, retreats, and training for psychedelic-assisted therapy. The clear message: healing is not just about the drug—it’s about the context, the support, and the integration that follows.
Colorado’s Bold Moves
Colorado’s Governor Jared Polis played a key role at the event, highlighting the state’s leadership in psychedelic reform. Polis made headlines by announcing pardons for state-level convictions involving psilocybin and psilocin possession for adults over 21.
Colorado remains the only state with a fully legalized pathway to psychedelic-assisted therapy using natural medicines. The state now has licensed facilitators, mushroom cultivation centers, and testing labs—all contributing to a growing regulated industry.
Looking Ahead: Ibogaine on the Horizon
One of the most talked-about future therapies at Psychedelic Science 2025 was ibogaine, a potent psychedelic derived from an African plant traditionally used in spiritual rituals. Unlike psilocybin, which lasts several hours, ibogaine experiences can stretch up to 24 hours and may hold potential for treating addiction, PTSD, and depression.
Texas recently allocated $50 million to study ibogaine for veterans, but experts suggest that Colorado might beat them to the punch with its already-operational psychedelic infrastructure. If so, the Centennial State could become the first to launch state-supported ibogaine therapy in the U.S.
A Movement in Transition
While Psychedelic Science 2025 may have felt less like a celebration and more like a strategy session, it marked a crucial moment for the psychedelic field. Leaders are acknowledging challenges, refining goals, and working toward integrating psychedelics into mainstream mental health care—responsibly and effectively.
With Colorado at the center of policy reform and ibogaine research gaining traction, the coming years could define whether psychedelics will reach their full potential in treating some of the most stubborn mental health challenges of our time.
Subscribe toIPN to stay update with Interventional Psychiatry.
Citations:
- On June 4, 2024, an FDA advisory panel voted against recommending MDMA-assisted therapy for PTSD. The Psychopharmacologic Drugs Advisory Committee was concerned about insufficient safety monitoring, potential bias in the trials, and ethical issues—including unblinding and misconduct—leading to a 9–2 vote on efficacy and a 10–1 vote that risks outweighed benefitsen.wikipedia.org+9en.wikipedia.org+9verywellhealth.com+9
- Ibogaine is being studied for treating substance-use disorders, particularly opioid addiction. A 2022 systematic review showed promise in reducing withdrawal symptoms and cravings, though concerns like cardiac risks and long QT syndrome underline the need for careful oversightarchives.nida.nih.gov+3en.wikipedia.org+3nida.nih.gov+3.